Patents by Inventor Mark Smyth
Mark Smyth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230042913Abstract: Disclosed are agents for treating or preventing cancers. More particularly, the present invention discloses therapeutic combinations comprising antagonists of receptor of NF-?B (RANK) ligand and immune checkpoint molecules in methods and compositions for treating or inhibiting the development, progression or recurrence of cancers, including metastatic cancers.Type: ApplicationFiled: June 5, 2018Publication date: February 9, 2023Inventors: Bill DOUGALL, Michele TENG, Elizabeth AHERN, Mark SMYTH
-
Publication number: 20220135642Abstract: The present disclosure relates generally to polypeptides, cells, compositions and methods for enhancing immune function, and in particular the immune function of T cells, such as CD8+ T cells. More particularly, the present invention relates to modified DNAM-1 polypeptides, T cells expressing recombinant and/or modified DNAM-1, and methods of using these cells in adoptive T cell transfer, such as for the treatment of cancer or infection. The disclosure also relates to methods for preparing T cells with enhanced immune function; methods for preparing T cells for adoptive cell therapy; methods for assessing the immune function of T cells in a subject or cell population; methods for predicting the responsiveness of a subject with cancer to cancer therapy; and methods for predicting the survival or survival time of a subject with cancer.Type: ApplicationFiled: February 27, 2020Publication date: May 5, 2022Inventors: Tobias Bald, Matthias Braun, Mark Smyth
-
Publication number: 20210047403Abstract: A method of reducing or relieving immune inhibition in a mammal includes the step of at least partly inhibiting or reducing CD96 activity in one or more cells of the mammal to thereby relieve immune inhibition and/or enhance or restore immune surveillance in the mammal. Typically, inhibiting or reducing CD96 activity does not include, or depend upon, killing of CD96-expressing cells in the mammal. The method relieves immune inhibition and/or enhances or restores immune surveillance in the mammal to thereby treat or prevent cancer or cancer metastasis and/or a viral infection in the mammal. Also provided is a method of screening, designing, engineering or otherwise producing a CD96-inhibitory agent that relieves immune inhibition and/or enhances or restores immune surveillance in a mammal.Type: ApplicationFiled: July 24, 2020Publication date: February 18, 2021Applicant: The Council of the Queensland Institute of Medical ResearchInventor: Mark Smyth
-
Publication number: 20180022818Abstract: The present invention provides a catalyst precursor and a catalyst suitable for preparing multi-wall carbon nanotubes. The resulting multi-wall carbon nanotubes have a narrow distribution as to the number of walls forming the tubes and a narrow distribution in the range of diameters for the tubes. Additionally, the present invention provides methods for producing multi-wall carbon nanotubes having narrow distributions in the number of walls and diameters. Further, the present invention provides a composition of spent catalyst carrying multi-wall nanotubes having narrow distribution ranges of walls and diameters.Type: ApplicationFiled: July 21, 2017Publication date: January 25, 2018Applicant: Adelaide Research & Innovation Pty LtdInventors: Shaun Reuss McColl, Ian Comerford, Yuka Harata-Lee, Mark Smyth
-
Patent number: 9718887Abstract: The present disclosure relates to the prevention and/or treatment of metastatic cancer. Certain example embodiments of the present disclosure provide a method for preventing and/or treating a metastatic cancer in a subject. The method comprises administering to the subject a therapeutically effective amount of an inhibitor of a chemokine receptor CCX-CKR.Type: GrantFiled: September 6, 2013Date of Patent: August 1, 2017Assignees: Adelaide Research & Innovation PTY LTD, Peter Maccallum Cancer InstituteInventors: Shaun Reuss Mccoll, Ian Comerford, Yuka Harata-Lee, Mark Smyth
-
Patent number: 9540382Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.Type: GrantFiled: June 3, 2013Date of Patent: January 10, 2017Assignee: Pharmacyclics LLCInventors: Norbert Purro, Mark Smyth, Erick Goldman, David D. Wirth
-
Patent number: 9296753Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.Type: GrantFiled: June 3, 2013Date of Patent: March 29, 2016Assignee: Pharmacyclics LLCInventors: Mark Smyth, Erick Goldman, David D. Wirth, Norbert Purro
-
Publication number: 20150291698Abstract: The present disclosure relates to the prevention and/or treatment of metastatic cancer. Certain example embodiments of the present disclosure provide a method for preventing and/or treating a metastatic cancer in a subject. The method comprises administering to the subject a therapeutically effective amount of an inhibitor of a chemokine receptor CCX-CKR.Type: ApplicationFiled: September 6, 2013Publication date: October 15, 2015Applicants: Peter MacCallum Cancer Institute, Adelaide Research & Innovation Pty LtdInventors: Shaun Reuss Mccoll, Ian Comerford, Yuka Harata-Lee, Mark Smyth
-
Publication number: 20150158871Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.Type: ApplicationFiled: June 3, 2013Publication date: June 11, 2015Inventors: Norbert Purro, Mark Smyth, Erick Goldman, David D. Wirth
-
Patent number: 9007096Abstract: An apparatus relating generally to voltage conversion includes an amplifier coupled to receive an input voltage and a reference voltage. First and second converters are coupled to the amplifier to receive a bias voltage. The first converter includes a first transconductor coupled to receive the bias voltage to adjust a first tail current, and a first differential input. A first inverter of the first converter has a first feedback device coupled input-to-output to provide a first transimpedance amplifier load. The first inverter is coupled to the first transconductor. The second converter includes a second transconductor coupled to receive the bias voltage to adjust a second tail current, and a second differential input. A second inverter of the second converter has a second feedback device coupled input-to-output to provide a second transimpedance amplifier load. The second inverter is coupled to the second transconductor.Type: GrantFiled: July 7, 2014Date of Patent: April 14, 2015Assignee: Xilinx, Inc.Inventors: Declan Carey, Thomas Mallard, Mark Smyth, James Hudner
-
Publication number: 20140336203Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.Type: ApplicationFiled: July 23, 2014Publication date: November 13, 2014Inventors: Mark SMYTH, Erick GOLDMAN, David D. WIRTH, Norbert PURRO
-
Publication number: 20130338172Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.Type: ApplicationFiled: June 3, 2013Publication date: December 19, 2013Applicant: Pharmacyclics, Inc.Inventors: Mark Smyth, Erick Goldman, David D. Wirth, Norbert Purro
-
Publication number: 20080090785Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsinlike activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.Type: ApplicationFiled: May 9, 2005Publication date: April 17, 2008Applicant: Proteolix, Inc.Inventors: Mark Smyth, Guy Laidig, Ronald Borchardt, Barry Bunin, Craig Crews, John Musser, Kevin Shenk, Peggy Radel
-
Publication number: 20070293465Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.Type: ApplicationFiled: June 19, 2007Publication date: December 20, 2007Applicant: Proteolix, Inc.Inventors: Kevin Shenk, Francesco Parlati, Han-Jie Zhou, Catherine Sylvain, Mark Smyth, Mark Bennett, Guy Laidig
-
Publication number: 20070196337Abstract: The present invention relates to retroviral vectors capable of driving the expression of perforin in a cell and a method of expressing recombinant perforin in a cell. The present invention also relates to recombinant perforin polypeptides and nucleic acid molecules derived therefrom and uses thereof. Also encompassed are screening assays employing such recombinant perforin molecules, compounds identified by the screening assays and uses thereof.Type: ApplicationFiled: August 30, 2006Publication date: August 23, 2007Inventors: Joseph Trapani, Mark Smyth
-
Publication number: 20070191284Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.Type: ApplicationFiled: April 11, 2007Publication date: August 16, 2007Applicant: Proteolix, Inc.Inventors: Mark Smyth, Guy Laidig, Ronald Borchardt, Barry Bunin, Craig Crews, John Musser
-
Publication number: 20060088471Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus, such as a detectable label. Along with therapeutic utilities, these peptide based compounds can be used in assays useful for screening, monitoring, diagnostic and/or dosing purposes.Type: ApplicationFiled: October 19, 2005Publication date: April 27, 2006Applicant: Proteolix, Inc.Inventors: Mark Bennett, Tonia Buchholz, Susan Demo, Guy Laidig, Evan Lewis, Mark Smyth
-
Publication number: 20060030533Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.Type: ApplicationFiled: August 8, 2005Publication date: February 9, 2006Applicant: Proteolix, Inc.Inventors: Mark Smyth, Guy Laidig
-
Publication number: 20050256324Abstract: This invention relates to methods for the preparation of amino acid keto-epoxides. Specifically, allylic ketones are stereoselectively converted to the desired keto epoxides.Type: ApplicationFiled: May 17, 2005Publication date: November 17, 2005Applicant: Proteolix, Inc.Inventors: Guy Laidig, Peggy Radel, Mark Smyth
-
Publication number: 20050245435Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.Type: ApplicationFiled: April 14, 2005Publication date: November 3, 2005Applicant: Proteolix, Inc.Inventors: Mark Smyth, Guy Laidig, Ronald Borchardt, Barry Bunin, Craig Crews, John Musser, John Schneekloth, John Chabala